Nasal Spray by Glenmark
Mumbai-based pharmaceutical company Glenmark and its partner Canadian biotech firm SaNOtize research launched nitric oxide nasal spray (NONS) for the treatment of COVID-19 patients.
The partners have launched the product under the brand name FabiSpray. The market price of FabiSpray will be Rs. 850 per unit.
Manufacturing and marketing approval was given by the Drugs Controller General of India (DCGI) for nitric oxide nasal spray (NONS) earlier to accelerate the approval process.
“FabiSpray, is designed to kill the COVID-19 virus in the upper airways. It has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2. NONS when sprayed over nasal mucosa, acts as a physical and chemical barrier against the virus, preventing it from incubating and spreading to lungs”, said the drug manufacturer in the statement.
